All Oncology News

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Jamile M. Shammo, MD, discusses how the differences between the available JAK inhibitors in myelofibrosis guide her treatment considerations.

USC Norris Comprehensive Cancer Center has opened Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging, a radiation oncology center.

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Bria-IMT plus retifanlimab generated a potential overall survival benefit in heavily pretreated, metastatic hormone receptor–positive breast cancer.

The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.

Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Sylvester Comprehensive Cancer Center has opened a clinical trial for patients with high-grade neuroendocrine cancers evaluating an oncolytic virus.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.